SEC For																			
	FORM	4	UNITED STATES SECURITIES AND EXCHANGE COMM Washington, D.C. 20549												OMB	APPRO\	/AI		
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).					Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940														
1. Name and Address of Reporting Person* Fisher Stewart					2. Issuer Name and Ticker or Trading Symbol C4 Therapeutics, Inc. [ CCCC ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
	/O C4 THERAPEUTICS, INC.				3. Date of Earliest Transaction (Month/Day/Year) 03/07/2024  4. If Amendment, Date of Original Filed (Month/Day/Year)								X     Officer (give title below)     Other (specific)       Chief Scientific Officer     6. Individual or Joint/Group Filing (Check Applicable)						
490 ARSENAL WAY #120 (Street)													S. Individual of Joint/Group Filing (Check Applicable Line)     X   Form filed by One Reporting Person     Form filed by More than One Reporting Person						
WATERTOWN MA			02472		Rule 10b5-1(c) Transaction Indication														
(City) (State) (Zip)					Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		-	Fable I - Nor	n-Deriva	tive S	Securiti	ies Acq	uired,	Dis	oosed of,	or Bene	eficially	Owned						
1. Title of Security (Instr. 3)				2. Transad Date (Month/Da		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			5. Amount Securities Beneficiall Owned Fol	Form ly (D)		Direct I Indirect I tr. 4) (	7. Nature of ndirect Beneficial Dwnership		
								Code	v	Amount (A) or (D)		Price	Reported Transactio (Instr. 3 an	ction(s)			(Instr. 4)		
			Table II -										wned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	4. Trans Code	action	5. Number Derivativ Securitie Acquired Disposed (Instr. 3,	er of re es d (A) or d of (D)	6. Date Exer Expiration D (Month/Day/		ate of Securities		d Amount ies g Security	8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securitie Beneficia Owned Followin Reported	ve es ally Ig	ly Ownershi Form: Direct (D) or Indirec	Beneficial Ownership t (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)					
Stock Option (Right to Buy)	\$45.54	03/07/2024		<b>D</b> <sup>(1)</sup>			94,950	(2)		02/10/2031	Common Stock	94,950	\$0 <sup>(1)</sup>	0		D			
Stock Option (Right to Buy)	\$19	03/07/2024		<b>A</b> <sup>(1)</sup>		94,950		(2)		02/10/2031	Common Stock	94,950	\$0 <sup>(1)</sup>	94,950		D			
Stock Option (Right to Buy)	\$22.71	03/07/2024		D <sup>(1)</sup>			118,000	(3)		02/13/2032	Common Stock	118,000	\$0 <sup>(1)</sup>	0		D			
Stock Option (Right to Buy)	\$19	03/07/2024		<b>A</b> <sup>(1)</sup>		118,000		(3)		02/13/2032	Common Stock	118,000	\$0 <sup>(1)</sup>	118,000		D			

## Explanation of Responses:

1. On March 7, 2024, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

2. This option shall vest and become exercisable in 16 equal quarterly installments, with the first installment vesting on May 11, 2021.

3. The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2022.

Remarks:

## /s/ Jolie M. Siegel, Attorney-in-03/08/2024 Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.